194 related articles for article (PubMed ID: 36849806)
1. Risk factors for a severe disease course in children with SARS-COV-2 infection following hematopoietic cell transplantation in the pre-Omicron period: a prospective multinational Infectious Disease Working Party from the European Society for Blood and Marrow Transplantation group (EBMT) and the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH) study.
Averbuch D; de la Camara R; Tridello G; Knelange NS; Bykova TA; Ifversen M; Dobsinska V; Ayas M; Hamidieh AA; Pichler H; Perez-Martinez A; Cesaro S; Sundin M; Badell I; Bader P; Johansson JE; Mirci-Danicar O; Sedlacek P; Paillard C; Gibson B; Lawson S; Kroeger N; Corbacioglu S; Mikulska M; Piñana JL; Styczynski J; Ljungman P
Bone Marrow Transplant; 2023 May; 58(5):558-566. PubMed ID: 36849806
[TBL] [Abstract][Full Text] [Related]
2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
Ljungman P; de la Camara R; Mikulska M; Tridello G; Aguado B; Zahrani MA; Apperley J; Berceanu A; Bofarull RM; Calbacho M; Ciceri F; Lopez-Corral L; Crippa C; Fox ML; Grassi A; Jimenez MJ; Demir SK; Kwon M; Llamas CV; Lorenzo JLL; Mielke S; Orchard K; Porras RP; Vallisa D; Xhaard A; Knelange NS; Cedillo A; Kröger N; Piñana JL; Styczynski J
Leukemia; 2021 Oct; 35(10):2885-2894. PubMed ID: 34079042
[TBL] [Abstract][Full Text] [Related]
4. Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.
Huang A; Cicin-Sain C; Pasin C; Epp S; Audigé A; Müller NJ; Nilsson J; Bankova A; Wolfensberger N; Vilinovszki O; Nair G; Hockl P; Schanz U; Kouyos RD; Hasse B; Zinkernagel AS; Trkola A; Manz MG; Abela IA; Müller AMS
Transplant Cell Ther; 2022 Apr; 28(4):214.e1-214.e11. PubMed ID: 35092892
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
[TBL] [Abstract][Full Text] [Related]
6. Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection.
Shah N; Dahi PB; Ponce DM; Sauter CS; Shaffer BC; Chung DJ; Politikos I; Lin RJ; Giralt SA; Papanicolaou G; Ramanathan LV; Perales MA; Kamboj M; Shah GL; Gyurkocza B
Transplant Cell Ther; 2022 Jan; 28(1):55.e1-55.e5. PubMed ID: 34649021
[TBL] [Abstract][Full Text] [Related]
7. Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia.
Oltolini C; Acerbis A; Orofino G; Racca S; Noviello M; Dispinseri S; Clementi N; Piemontese S; Xue E; Giglio F; Lupo Stanghellini MT; Diral E; Bruno A; Tassi E; Beretta V; Marzinotto I; Scarlatti G; Lampasona V; Ardemagni A; Sampaolo M; Bonini C; Corti C; Peccatori J; Castagna A; Ciceri F; Greco R
Front Immunol; 2023; 14():1184956. PubMed ID: 37287986
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study.
Fan S; Mo X; Zhang X; Xu L; Wang Y; Yan C; Chen H; Zhang Y; Cheng Y; Sun Y; Chen Y; Chen Y; Han W; Wang J; Wang F; Xu Z; Huang X
Ann Hematol; 2024 Apr; 103(4):1333-1344. PubMed ID: 38381172
[TBL] [Abstract][Full Text] [Related]
9. Improved outcomes over time and higher mortality in CMV seropositive allogeneic stem cell transplantation patients with COVID-19; An infectious disease working party study from the European Society for Blood and Marrow Transplantation registry.
Ljungman P; Tridello G; Piñana JL; Ciceri F; Sengeloev H; Kulagin A; Mielke S; Yegin ZA; Collin M; Einardottir S; Lepretre SD; Maertens J; Campos A; Metafuni E; Pichler H; Folber F; Solano C; Nicholson E; Yüksel MK; Carlson K; Aguado B; Besley C; Byrne J; Heras I; Dignan F; Kröger N; Robin C; Khan A; Lenhoff S; Grassi A; Dobsinska V; Miranda N; Jimenez MJ; Yonal-Hindilerden I; Wilson K; Averbuch D; Cesaro S; Xhaard A; Knelange N; Styczynski J; Mikulska M; de la Camara R
Front Immunol; 2023; 14():1125824. PubMed ID: 36960069
[TBL] [Abstract][Full Text] [Related]
10. Three doses of a recombinant conjugated SARS-CoV-2 vaccine early after allogeneic hematopoietic stem cell transplantation: predicting indicators of a high serologic response-a prospective, single-arm study.
Barkhordar M; Chahardouli B; Biglari A; Ahmadvand M; Bahri T; Alaeddini F; Sharifi Aliabadi L; Noorani SS; Bagheri Amiri F; Biglari M; Shemshadi MR; Ghavamzadeh A; Vaezi M
Front Immunol; 2023; 14():1169666. PubMed ID: 37153556
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 disease in children and adolescents following allogeneic hematopoietic stem cell transplantation: A report from the Turkish pediatric bone marrow transplantation study group.
Bozkurt C; Hazar V; Malbora B; Küpesiz A; Aygüneş U; Fışgın T; Karakükçü M; Kuşkonmaz B; Kılıç SÇ; Bayırlı D; Arman Bilir Ö; Yalçın K; Gözmen S; Uygun V; Elli M; Sarbay H; Küpesiz FT; Şaşmaz Hİ; Aksoy BA; Yılmaz E; Okur FV; Tekkeşin F; Yenigürbüz FD; Özek G; Atay AA; Bozkaya İO; Çelen S; Öztürkmen S; Güneş AM; Gürsel O; Güler E; Özcan A; Çetinkaya DU; Aydoğdu S; Özbek NY; Karasu G; Sezgin G; Doğru Ö; Albayrak D; Öztürk G; Aksoylar S; Daloğlu H; Odaman Al I; Evim MS; Akbayram S; Öncül Y; Zengin E; Albayrak C; Timur Ç; Kar YD; Çakmaklı HF; Tüfekçi Ö; Töret E; Antmen B
Pediatr Transplant; 2024 May; 28(3):e14758. PubMed ID: 38659218
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 in children with cancer or after haematopoietic stem cell transplant: An analysis of 131 patients.
Haeusler GM; Ammann RA; Carlesse F; Groll AH; Averbuch D; Castagnola E; Agyeman PKA; Phillips B; Gilli F; Solopova G; Attarbaschi A; Wegehaupt O; Speckmann C; Sung L; Lehrnbecher T
Eur J Cancer; 2021 Dec; 159():78-86. PubMed ID: 34736044
[TBL] [Abstract][Full Text] [Related]
13. Pneumocystis Pneumonia After Allogeneic Hematopoietic Cell Transplantation: A Case-Control Study on Epidemiology and Risk Factors on Behalf of the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation.
Robin C; Cordonnier C; Tridello G; Knelange N; Xhaard A; Chantepie S; Tanguy-Schmidt A; Schouten HC; Yeshurun M; Rocha V; Srour M; Kröger N; Ledoux MP; Dalgaard J; Thiebaut A; Giardino S; Calore E; Zuckerman T; Groll AH; Raida L; Avcin S; Vicent MG; Kaare A; Drozd-Sokolowska J; Turlure P; Bretagne S; Mikulska M; Camara R; Cesaro S; Styczynski J
Transplant Cell Ther; 2024 Feb; 30(2):235.e1-235.e10. PubMed ID: 38007092
[TBL] [Abstract][Full Text] [Related]
14. Current attitude to deferral of cellular therapy or nontransplant chemotherapy due to SARS-CoV-2 asymptomatic infection: Survey of Infectious Diseases Working Party EBMT.
Styczynski J; Cesaro S; von Lilienfeld-Toal M; Marchesi F; Gil L; Mikulska M; Knelange N; Wendel L; Averbuch D; de la Camara R
Transpl Infect Dis; 2022 Apr; 24(2):e13773. PubMed ID: 34918856
[TBL] [Abstract][Full Text] [Related]
15. Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy.
Camargo JF; Mendoza MA; Lin R; Moroz IV; Anderson AD; Morris MI; Natori Y; Natori A; Raja M; Lekakis L; Beitinjaneh A; Jimenez A; Goodman M; Wang T; Komanduri KV; Pereira D
Transpl Infect Dis; 2021 Aug; 23(4):e13625. PubMed ID: 33896088
[TBL] [Abstract][Full Text] [Related]
16. Early administration of SARS-CoV-2 monoclonal antibody reduces the risk of mortality in hematologic malignancy and hematopoietic cell transplant patients with COVID-19.
Jabr R; Khatri A; Anderson AD; Garcia LC; Viotti JB; Natori Y; Raja M; Camargo JF; Morris MI
Transpl Infect Dis; 2023 Feb; 25(1):e14006. PubMed ID: 36704987
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid does not reduce SARS-CoV-2 infection in newly allogeneic hematopoietic stem cell transplantation recipients: a prospective NICHE cohort.
Gao H; Wang J; Zheng X; Pei X; Zheng Y; Zhai W; Zhang R; Chen X; Ma Q; Wei J; Yang D; Pang A; He Y; Feng S; Cao Y; Jiang E
Front Cell Infect Microbiol; 2024; 14():1324019. PubMed ID: 38505288
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
20. Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey.
Passweg JR; Baldomero H; Chabannon C; Corbacioglu S; de la Cámara R; Dolstra H; Glass B; Greco R; Mohty M; Neven B; Peffault de Latour R; Perić Z; Snowden JA; Yakoub-Agha I; Sureda A; Kröger N;
Bone Marrow Transplant; 2022 May; 57(5):742-752. PubMed ID: 35194156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
